Uncategorized
Next Generation Drug Conjugates Market Worth USD 7.94 Billion to 2031 – Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Next Generation Drug Conjugates Market – By Type (Peptide Receptor Radionuclide Therapy, Ligand mediated RNAi Conjugate, Ligand Conjugated Anti Sense Medicine and Peptide Drug Conjugate), By Type of Targeting Ligand (Amino Sugar, Peptide, Lipid, Small Molecule and Virus-like Particles), By Type of Payload (Peptide, Small Molecule, Oligonucleotide, Radionuclide), By Type of Therapy (Monotherapy, Combination Therapy), By Route of Administration, By Target Indications, By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031.”
According to the latest research by InsightAce Analytic, the Global Next Generation Drug Conjugates Market is valued at US$ 2.61 Bn in 2023, and it is expected to reach US$ 7.94 Bn by 2031, with a CAGR of 15.1% during the forecast period of 2024-2031.
Request for Free Sample Pages: https://www.insightaceanalytic.com/report/next-generation-drug-conjugates-market/2482
Next Generation Drug Conjugates Market Report Scope:
Report Attribute
Specifications
Market Size Value In 2023
USD 2.61 Bn
Revenue Forecast In 2031
USD 7.94 Bn
Growth Rate CAGR
CAGR of 15.1% from 2024 to 2031
Quantitative Units
Representation of revenue in US$ Mn and CAGR from 2024 to 2031
Historic Year
2019 to 2023
Forecast Year
2024-2031
Report Coverage
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends
Segments Covered
By Type, By Targeting Ligand, By Payload, By Therapy, By Route of Administration, By Indications and By Region
Regional Scope
North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Country Scope
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea
Growth of the next-generation drug conjugates market is driven by several factors, such as the recent accelerated approvals of various next-generation drug conjugates and the keen interest shown by the big pharma players in forging strategic alliances with the next-generation drug conjugate developers.
The ever-growing rise in medicare costs, along with the increasing burden of rare disease indications, prompted the stakeholders to look for alternatives to conventional therapies. As a result, the next-generation conjugates combine cytotoxic drugs with targeting agents, enhancing drug efficacy while reducing systemic toxicity. Deeper cellular penetration and permeability have emerged as viable targeted therapeutics for rare disease indications, including cancers.
List of Prominent Players in the Next Generation Drug Conjugates Market:
Advanced Accelerator Applications
Alnylam Pharmaceuticals
Arrowhead Pharmaceuticals
Dicerna Pharmaceuticals
Geron Corporation
Ionis Pharmaceuticals
Dyne Therapeutics, Inc.
Ambrx Biopharma, Inc. (Johnson & Johnson Services, Inc.)
Vincerx Pharma
Tubulis Technologies
Nurix Therapeutics, Inc.
Other Prominent Players
Order 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/2482
Market Dynamics:
Drivers:
The growth of the next generation drug conjugates (NGDCs) market is driven by several key factors. Technological advancements, such as improved linker technologies and versatile applications, enhance drug efficacy and safety.
The rising prevalence of chronic diseases, particularly cancer and genetic disorders, fuels demand for targeted therapies. Strategic industry collaborations and acquisitions, like Pfizer’s purchase of Seagen, accelerate innovation and market expansion. Favorable regulatory environments support expedited review processes and clear development guidelines. Additionally, significant investment in research and development, supported by funding and innovative platforms, drives the discovery and optimization of new NGDCs. These combined factors contribute to the rapid advancement and adoption of NGDCs in modern medicine.
Challenges:
The global next-generation drug conjugates market faces several formidable challenges. One of the primary obstacles is the high development cost associated with these therapies. The complex manufacturing processes required for drug conjugates involve sophisticated technology and stringent quality control measures, making scalability difficult and expensive. Additionally, the regulatory landscape presents significant hurdles; furthermore, gaining permission from regulatory bodies like the FDA and EMA is a time-consuming and expensive process that frequently necessitates substantial clinical trials to prove safety and efficacy.
Another major challenge is ensuring the stability and efficacy of drug conjugates. In order to be effective, these therapies must both release the therapeutic agent at the target site in a controlled manner and be stable under physiological conditions. Balancing these requirements while minimizing toxicity is a complex scientific and technical task. Patents and proprietary technology can restrict the capacity of new companies to enter the market and innovate, which further complicates intellectual property issues.
Regional Trends:
The North American next generation drug conjugates market is growing due to advanced healthcare infrastructure and significant R&D investments. Key players in the region are driving innovation in targeted cancer therapies, leveraging cutting-edge technologies for drug conjugation. The increasing cases of cancer and the rising demand for personalized medicine boost the market. Favorable regulatory policies further stimulate market growth, allowing swift approval and commercialization of novel drug conjugates.
Moreover, strategic collaborations between pharmaceutical companies and research institutions fuel the development of next-generation therapies. With a robust pipeline and expanding applications beyond oncology, the North American market for drug conjugates is poised for sustained expansion.
Curious About This Latest Version of The Report? Enquiry Before Buying:https://www.insightaceanalytic.com/enquiry-before-buying/2482
Recent Developments:
In April 2023, Novartis entered into a licensing agreement with 3B Pharmaceuticals. 3B Pharmaceuticals is a German-based company involved in the growth of peptide receptor radionuclide therapy (PRRT) candidates targeting fibroblast activation protein (FAP) receptors.
In March 2023, Japan-based PeptiDream signed strategic partnership with US-based RayzeBio to develop a peptide-radioisotope (RI) conjugate against Glypican-3 (“GPC3”) expressed in liver cancers.
In March 2023, The USFDA accepted Ionis Pharmaceutical’s New Drug Application (NDA) for its investigational antisense medication Eplontersen, which is intended for patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). After Amvuttra (vutrisiran) from Alnylam, Eplontersen will be the second medication licensed for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
For More Customization @ https://www.insightaceanalytic.com/customisation/2482
Segmentation of Next Generation Drug Conjugates Market-
Next Generation Drug Conjugates Market- By Type
Peptide Receptor Radionuclide Therapy (Peptide Radionuclide Conjugate)
Ligand-mediated RNAi Conjugate
Ligand Conjugated Antisense Medicine
Peptide Drug Conjugate
Next Generation Drug Conjugates Market- By Targeting Ligand
Amino Sugar
Lipid
Peptide
Small Molecule
Virus-like Particles
Next Generation Drug Conjugates Market- By Payload
Peptide
Small Molecule
Oligonucleotide
Radionuclide
Next Generation Drug Conjugates Market- By Therapy
Monotherapy
Combination Therapy
Next Generation Drug Conjugates Market- By Route of Administration
Intravenous
Subcutaneous
Others
Next Generation Drug Conjugates Market- By Indications
Gastroenteropancreatic Neuroendocrine Tumors
Prostate Cancer
Leptomeningeal Carcinomatosis caused by Breast Cancer Brain Metastases
Hereditary Transthyretin Amyloidosis
Atherosclerotic Cardiovascular Diseases
Severe Hypertriglyceridemia
Hereditary Angioedema
Acute Hepatic Porphyria
Primary Hyperoxaluria
Heterozygous Familial Hypercholesterolemia
Hemophilia
Low-Risk Myelodysplastic Syndrome
Myelofibrosis
Familial Chylomicronemia Syndrome
Alpha-1 Antitrypsin Deficiency Liver Disease
Next Generation Drug Conjugates Market- By Region
North America–
The US
Canada
Mexico
Europe–
Germany
The UK
France
Italy
Spain
Rest of Europe
Asia-Pacific–
China
Japan
India
South Korea
South East Asia
Rest of Asia Pacific
Latin America–
Brazil
Argentina
Rest of Latin America
Middle East & Africa–
GCC Countries
South Africa
Rest of Middle East and Africa
Why should buy this report:
To receive a comprehensive analysis of the prospects for global next generation drug conjugates market
To receive industry overview and future trends of global next generation drug conjugates market
To analyze the next generation drug conjugates market drivers and challenges
To get information on the next generation drug conjugates market size value (US$ Mn) forecast till 2031
Major Investments, Mergers & Acquisition in global next generation drug conjugates market industry
Other Related Reports Published by InsightAce Analytic:
Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market
Conjugation and Labeling Services Market
Peptide–Drug Conjugates (PDCs) Market
Antibody Discovery Market
The post Next Generation Drug Conjugates Market Worth USD 7.94 Billion to 2031 – Exclusive Report by InsightAce Analytic Pvt. Ltd. appeared first on HIPTHER Alerts.